185 related articles for article (PubMed ID: 37962553)
21. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation.
Cameron ST; Critchley HO; Buckley CH; Kelly RW; Baird DT
Fertil Steril; 1997 Jun; 67(6):1046-53. PubMed ID: 9176442
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Dao B; Vanage G; Li XJ; Bardin CW; Koide SS
Contraception; 1997 Jan; 55(1):35-40. PubMed ID: 9013059
[TBL] [Abstract][Full Text] [Related]
23. Progesterone Receptor Isoforms A and B in Pancreatic Neuroendocrine Tumor.
Yazdani S; Kasajima A; Ogata H; Felizola SJ; Nakamura Y; Onodera Y; Watanabe M; Motoi F; Unno M; Sasano H
Neuroendocrinology; 2015; 101(4):309-20. PubMed ID: 25791399
[TBL] [Abstract][Full Text] [Related]
24. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Poole AJ; Li Y; Kim Y; Lin SC; Lee WH; Lee EY
Science; 2006 Dec; 314(5804):1467-70. PubMed ID: 17138902
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
26. Ovarian steroid hormones modulate the expression of progesterone receptors and histone acetylation patterns in uterine leiomyoma cells.
Sant'Anna GDS; Brum IS; Branchini G; Pizzolato LS; Capp E; Corleta HVE
Gynecol Endocrinol; 2017 Aug; 33(8):629-633. PubMed ID: 28300476
[TBL] [Abstract][Full Text] [Related]
27. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma.
Koivisto-Korander R; Leminen A; Heikinheimo O
Obstet Gynecol; 2007 Feb; 109(2 Pt2):512-4. PubMed ID: 17267877
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study.
Perrault D; Eisenhauer EA; Pritchard KI; Panasci L; Norris B; Vandenberg T; Fisher B
J Clin Oncol; 1996 Oct; 14(10):2709-12. PubMed ID: 8874331
[TBL] [Abstract][Full Text] [Related]
29. Progesterone receptor modulators for endometriosis.
Fu J; Song H; Zhou M; Zhu H; Wang Y; Chen H; Huang W
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD009881. PubMed ID: 28742263
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice.
El Etreby MF; Liang Y; Johnson MH; Lewis RW
Prostate; 2000 Feb; 42(2):99-106. PubMed ID: 10617866
[TBL] [Abstract][Full Text] [Related]
31. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Bartlett TE; Evans I; Jones A; Barrett JE; Haran S; Reisel D; Papaikonomou K; Jones L; Herzog C; Pashayan N; Simões BM; Clarke RB; Evans DG; Ghezelayagh TS; Ponandai-Srinivasan S; Boggavarapu NR; Lalitkumar PG; Howell SJ; Risques RA; Rådestad AF; Dubeau L; Gemzell-Danielsson K; Widschwendter M
Genome Med; 2022 Jun; 14(1):64. PubMed ID: 35701800
[TBL] [Abstract][Full Text] [Related]
32. The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature.
Yuan H; Upadhyay G; Lu J; Kopelovich L; Glazer RI
Cancer Prev Res (Phila); 2012 May; 5(5):754-64. PubMed ID: 22427346
[TBL] [Abstract][Full Text] [Related]
33. Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.
Sahores A; Figueroa V; May M; Liguori M; Rubstein A; Fuentes C; Jacobsen BM; Elía A; Rojas P; Sequeira GR; Álvarez MM; González P; Gass H; Hewitt S; Molinolo A; Lanari C; Lamb CA
Horm Cancer; 2018 Oct; 9(5):338-348. PubMed ID: 29956066
[TBL] [Abstract][Full Text] [Related]
34. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
[TBL] [Abstract][Full Text] [Related]
35. Progesterone antagonists and progesterone receptor modulators: an overview.
Spitz IM
Steroids; 2003 Nov; 68(10-13):981-93. PubMed ID: 14667991
[TBL] [Abstract][Full Text] [Related]
36. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
37. Mifepristone: antineoplastic studies.
Sartor O; Figg WD
Clin Obstet Gynecol; 1996 Jun; 39(2):498-505. PubMed ID: 8734014
[TBL] [Abstract][Full Text] [Related]
38. Effect of follicular phase administration of mifepristone (RU486) on blastocyst implantation in the rhesus monkey.
Ghosh D; Nayak NR; Sengupta J
Contraception; 1997 Aug; 56(2):117-22. PubMed ID: 9315421
[TBL] [Abstract][Full Text] [Related]
39. Differential quantitative proteomics reveals key proteins related to phenotypic changes of breast cancer cells expressing progesterone receptor A.
Pateetin P; Pisitkun T; McGowan E; Boonyaratanakornkit V
J Steroid Biochem Mol Biol; 2020 Apr; 198():105560. PubMed ID: 31809870
[TBL] [Abstract][Full Text] [Related]
40. Steroid hormone receptors in breast cancer management.
Osborne CK
Breast Cancer Res Treat; 1998; 51(3):227-38. PubMed ID: 10068081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
